Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015, Article ID 327287, 12 pages
http://dx.doi.org/10.1155/2015/327287
Research Article

MicroRNA-155 Hallmarks Promising Accuracy for the Diagnosis of Various Carcinomas: Results from a Meta-Analysis

1Department of Preventive Medicine, Fujian Province Key Lab of Environment and Health, Institution of Environment and Health, Major Subject of Environment and Health of Fujian Key Universities, School of Public Health, Fujian Medical University, No. 1 Xue Yuan Road, University Town, Fuzhou, Fujian 350108, China
2School of Postgraduate Education, Fujian Medical University, No. 1 Xue Yuan Road, University Town, Fuzhou, Fujian 350108, China

Received 24 December 2014; Accepted 27 February 2015

Academic Editor: Marco E. M. Peluso

Copyright © 2015 Chuancheng Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Recent studies have shown that microRNAs (miRNAs) have diagnostic values in various cancers. This meta-analysis seeks to summarize the global diagnostic role of miR-155 in patients with a variety of carcinomas. Methods. Eligible studies were retrieved by searching the online databases, and the bivariate meta-analysis model was employed to generate the summary receiver operator characteristic (SROC) curve. Results. A total of 17 studies dealing with various carcinomas were finally included. The results showed that single miR-155 testing allowed for the discrimination between cancer patients and healthy donors with a sensitivity of 0.82 (95% CI: 0.73–0.88) and specificity of 0.77 (95% CI: 0.70–0.83), corresponding to an area under curve (AUC) of 0.85, while a panel comprising expressions of miR-155 yielded a sensitivity of 0.76 (95% CI: 0.68–0.82) and specificity of 0.82 (95% CI: 0.77–0.86) in diagnosing cancers. The subgroup analysis displayed that serum miR-155 test harvested higher accuracy than plasma-based assay (the AUC, sensitivity, and specificity were, resp., 0.87 versus 0.73, 0.78 versus 0.74, and 0.77 versus 0.70). Conclusions. Our data suggest that single miR-155 profiling has a potential to be used as a screening test for various carcinomas, and parallel testing of miR-155 confers an improved specificity compared to single miR-155 analysis.